Pharmacotherapy for thyroid nodules. A systematic review and meta-analysis

Area of Science:

• Endocrinology
• Thyroidology

Background:

• Nodular thyroid disease management involves uncertainty.
• Thyroxine suppressive treatment is used to reduce thyroid nodules, with varied efficacy.
• The TSH dependency in benign versus malignant nodules is not fully understood.

Purpose of the Study:

• To review the current understanding and uncertainties in managing nodular thyroid disease with thyroxine suppressive treatment.
• To evaluate the potential benefits and risks of TSH suppression in patients with thyroid nodules.

Main Methods:

• Systematic review of existing literature on thyroxine suppressive treatment for nodular thyroid disease.
• Analysis of follow-up data for benign nodules over a 10-year period.
• Assessment of potential adverse effects of TSH suppression, including hyperthyroidism, bone density reduction, and atrial fibrillation.

Main Results:

• Most benign nodules remain stable, shrink, or disappear over time without intervention.
• Thyroxine therapy may reduce nodule size and perinodular volume, potentially improving symptoms and cosmetic concerns.
• Significant risks associated with TSH suppression include hyperthyroidism, reduced bone density, and atrial fibrillation.

Conclusions:

• High-quality, long-duration studies are needed to clarify the role of suppressive therapy in nodular thyroid disease.
• Uncertainty regarding predictors of response and impact on patient-important outcomes questions the routine use of suppressive therapy.
• Future research should prioritize patient-centered outcomes, including thyroid cancer incidence, quality of life, and costs.